Eli Lilly presented new Phase 3 study data showing that Trulicity (dulaglutide) 1.5mg significantly lowered HbA1c and body weight as an add-on to insulin glargine without increasing the risk of low blood sugar after 28 weeks vs. placebo plus insulin glargine

The AWARD-9 study (n=300) was a randomized, double-blind, placebo-controlled, 28-week study that evaluated the efficacy and safety of once-weekly Trulicity 1.5mg as an add-on to insulin glargine vs. placebo plus insulin glargine. The primary objective was to demonstrate superiority of Trulicity on HbA1c reduction in patients with type 2 diabetes inadequately treated with insulin glargine, with or without metformin. 

Related Articles

After 28 weeks, Trulicity plus insulin significantly reduced HbA1c from baseline vs. placebo plus insulin (1.44% vs. 0.67%). Also, significantly more patients treated with Trulicity plus insulin achieved HbA1c <7% vs. placebo plus insulin (69.3% vs. 35.1%). Significant reductions in fasting serum glucose levels were seen in patients treated with Trulicity plus insulin vs. placebo plus insulin (44.63mg/dL vs. 27.90mg/dL). Further, patients in the Trulicity arm experienced significant weight loss vs. patients in the placebo arm (-1.91kg vs. +0.50kg). 

In both groups, insulin glargine was titrated via a treat-to-target algorithm. After 28 weeks, patients treated with Trulicity took an average of 13.19 units less of insulin glargine vs. patients treated with placebo (51.42 units vs. 64.61 units).


Continue Reading

Trulicity, a glucagon-like peptide-1 (GLP-1) receptor agonist, is used along with diet and exercise for the treatment of type 2 diabetes. It is available as 0.75mg/0.5mL and 1.5mg/0.5mL strength solutions in single-dose pens and single-dose prefilled syringes.

For more information call (800) 545-5979 or visit Trulicity.com.